ArticleBioImpacts : BI2026
Classification of recurrent implantation failure patients using peripheral blood immunological and metabolic markers.
Article in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recurrent implantation failure (RIF) is a complex condition that makes it one of the most challenging cases in the field of infertility. The diagnosis of this condition with the immunological etiology may be aided by determining the endometrial immune profile for the classification of these patients. Current diagnostic approaches are based on invasive endometrial biopsies to classify patients into balanced, low, or over-immune activation profiles, which have limitations for routine use and serial monitoring. This study aimed to develop and validate a minimally invasive peripheral blood-based classification system using immunological and metabolic markers to mirror endometrial immune profiles in RIF patients. Methods: Endometrial tissue and peripheral blood samples were collected during the mid-luteal phase from 163 RIF patients and 28 fertile controls. Endometrial immune profiles were determined via RT-qPCR for IL-18, IL-15, TWEAK, Fn-14, and CD56, classifying RIF into balanced, low, and over-immune activation subgroups, with sample sizes of 32, 47, and 84 women, respectively. Peripheral blood was analyzed by flow cytometry to determine the Th1/Th2 ratio and NK cell percentage; by ELISA to measure nuclear antibodies (ANA, anti-dsDNA), phospholipid-related antibodies (anticardiolipin, anti-β2-glycoprotein I, antiphospholipid antibodies), thyroid-related antibodies (anti-TPO, anti-TG), anti-tissue transglutaminase (anti-TTG), and metabolites (S1P, adiponectin, leptin, PGE2, phosphatidylserine, IGF-1); and by spectrophotometry to quantify total phospholipids. Results: The over-immune activation group showed significantly elevated Th1/Th2 ratios, NK-cell percentages, and autoantibodies (ANA, anti-phospholipid, anti-β2-glycoprotein I, anti-TG, anti-TPO) compared to balanced and low-immune activation groups. Metabolic profiles revealed higher leptin, and total phospholipids but lower adiponectin, S1P, and PGE2 in over-immune activation group. The low-activation group exhibited lower Th1/Th2 ratios, reduced leptin, but elevated adiponectin, S1P, and PGE2 versus balanced and over-immune activation groups. No significant differences were found in phosphatidylserine or IGF-1 across groups. Conclusion: Our results demonstrate that peripheral blood immunological and metabolic markers can effectively distinguish RIF immune endotypes, offering a non-invasive alternative to endometrial biopsy for personalized assisted reproductive technology (ART) management and potentially improving implantation success through targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.